Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1991-1-22
|
| pubmed:abstractText |
In 19 patients with newly diagnosed Type I diabetes mellitus a single transfusion of 1.9 x 10(9) to 1.5 x 10(10) lymphocytes was performed. Fifteen Type I diabetic patients who did not receive a transfusion were used as controls. Anti-beta-cell cell-mediated cytotoxicity was measured using an insulin release assay. Stimulated C-peptide secretion (100 g glucose orally, 1 mg glucagon i.v.) was used to estimate residual beta-cell function. Both parameters were measured prior to transfusion and after 12 months. The transfusions were followed by a fall of cytotoxicity below the 95% confidence limit of the controls in 11 of the 19 patients ('responders') (15.7 +/- 1.7 ng insulin/islet/20 h vs 6.7 +/- 1.3 P less than 0.001), while the other eight transfused patients ('non-responders') (13.5 +/- 1.9 vs 17.1 +/- 2.9, ns) and the non-transfused control patients (11.6 +/- 1.1 vs 14.2 +/- 2.4, ns) displayed persistently high cytotoxicity levels. In the responder group a slight improvement in stimulated C-peptide secretion was observed (136 +/- 43 pmol/dl vs 148 +/- 38, ns) whereas in the non-responder (127 +/- 28 vs 106 +/- 25, ns) and in the control group (130 +/- 17 vs 97 +/- 19, P less than 0.05) the stimulated C-peptide responses declined during the 12-month follow-up. Thus, lymphocyte transfusion may have beneficial effects by suppressing anti-beta-cell cytotoxicity and preserving C-peptide secretion.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0896-8411
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
601-9
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2252528-Adolescent,
pubmed-meshheading:2252528-Adult,
pubmed-meshheading:2252528-Autoimmune Diseases,
pubmed-meshheading:2252528-Blood Transfusion,
pubmed-meshheading:2252528-C-Peptide,
pubmed-meshheading:2252528-Child,
pubmed-meshheading:2252528-Cytotoxicity, Immunologic,
pubmed-meshheading:2252528-Diabetes Mellitus, Type 1,
pubmed-meshheading:2252528-Female,
pubmed-meshheading:2252528-Follow-Up Studies,
pubmed-meshheading:2252528-Histocompatibility Testing,
pubmed-meshheading:2252528-Humans,
pubmed-meshheading:2252528-Insulin,
pubmed-meshheading:2252528-Islets of Langerhans,
pubmed-meshheading:2252528-Lymphocyte Transfusion,
pubmed-meshheading:2252528-Lymphocytes,
pubmed-meshheading:2252528-Male
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Lymphocyte transfusion in recent onset type I diabetes mellitus--a one-year follow-up of cell-mediated anti-islet cytotoxicity and C-peptide secretion.
|
| pubmed:affiliation |
City Hospital of Leipzig, GDR.
|
| pubmed:publicationType |
Journal Article
|